Infertility Drugs & Devices Market Report 2024-2034

Infertility Drugs & Devices Market Report 2024-2034

The Infertility Drugs & Devices Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

High cost of treatment

A single IVF cycle ranges from US$15,000 to US$30,000, depending on the centre and the patient needs. Medications constitute 35% of these charges and other additional costs such as genetic testing of the embryos and surgical procedures that increases the cost further. Also, the costs would also depend on number of cycles conducted that range from 1 to 6, which imposes heavy financial burden on the patients. Such high costs limit the use and appropriate treatment option for the patients restricting market growth. Whereas the insurance coverage especially in the U.S. depends on the coverage plans that the employer has offered. Semen analysis is usually covered. However, major parts of the treatment such as embryo transfer, mini-IVF costs, Full IVF cost, using donor egg costs are not completely covered under insurance. There is a growing demand from employers in the U.S. to also provide fertility treatment coverage.

Unsupportive Government Regulations

Government regulations in the form of funding, grants, policies, subsidies, insurance greatly impact the adoption of ART procedures. Lack of these support systems the access to treatment services is restricted and hence leads to limited adoption of these clinical services. For instance, in Japan, ART treatments were initiated to be covered under health insurance since April 2022 as a move to deal with low fertility rates. Prior to this, only eligible couples received partial subsidies for ART treatment due to focus on lower-income citizens in Japan. Similar norms were set up for ART subsidies in Korea and Taiwan. In the U.S. , only 15 states have authorized legislation to private insurers to cover partial or full costs of infertility treatments, however, type of coverage varies by state, with only 8 states authorizing reimbursement for ART. Most European countries allow gametes donation that includes eggs and sperms. Sperm donation is allowed in 20 EU states while Egg donation is permitted in 17 states of the total 27 EU states. These regulations limit the adoption of ART and hence act as a critical barrier in market growth.

What Questions Should You Ask before Buying a Market Research Report?

• How is the Infertility Drugs & Devices market evolving?
• What is driving and restraining the Infertility Drugs & Devices market?
• How will each Infertility Drugs & Devices submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each Infertility Drugs & Devices submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading Infertility Drugs & Devices markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Infertility Drugs & Devices projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of Infertility Drugs & Devices projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Infertility Drugs & Devices market?
• Where is the Infertility Drugs & Devices market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Infertility Drugs & Devices market today, and over the next 10 years:

• Our 351-page report provides 156 tables and 245 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Infertility Drugs & Devices prices and recent developments.

Segments Covered in the Report

Product

• Drugs
  - Gonadotropins
  
  - Aromatase Inhibitors
  
  - Selective Estrogen Receptor Modulators (SERMs)
  
  - Dopamine Agonists
  
  - Other drug classes


• Equipment
  - Microscopes
  
  - Imaging Systems
  
  - Sperm Analyzer Systems
  
  - Ovum Aspiration Pumps
  
  - Micromanipulator Systems
  
  - Incubators
  
  - Gas Analyzers
  
  - Laser Systems
  
  - Cryosystems
  
  - Sperm Separation Devices


• Media & Consumables
• Accessories

Procedure

• Assisted Reproductive Technology
  - IVF
  
  - Intracytoplasmic Sperm Injection
  
  - Surrogacy


• Artificial Insemination
  - Intrauterine
  
  - Intracervical
  
  - Intratubal


• Fertility Surgeries
  - Laparoscopy
  
  - Hysteroscopy
  
  - Varicocelectomy
  
  - Laparotomy
  
  - Tubal Ligation Reversal
  
  - Microsurgical Reconstruction


• Other Infertility Treatment Procedures

Patient

• Female
• Male

End-Use

• Fertility Centers
• Hospitals & Surgical Clinics
• Cryobanks
• Research Institutes

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Infertility Drugs & Devices Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• Abbott Laboratories
• Esco Micro Pte Ltd
• Ferring BV
• FUJIFILM Irvine Scientific
• Hamilton Thorne
• Merck KGaA
• The Baker Company
• The Cooper Companies, Inc.
• Thermo Fisher Scientific
• Vitrolife

Overall world revenue for Infertility Drugs & Devices Market, 2024 to 2034 in terms of value the market will surpass US$5.9 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Infertility Drugs & Devices Market, 2024 to 2034 report help you?

In summary, our 350+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Infertility Drugs & Devices Market, 2024 to 2034 Market, with forecasts for product, procedure, patient, end-use, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 16 key national markets – See forecasts for the Infertility Drugs & Devices Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, U.K., Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Infertility Drugs & Devices Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Infertility Drugs & Devices Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.